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ABSTRACT
Objective: Diabetes mellitus (DM) causes hyperglycemia, which is one of the most common diseases in the world. One of the strategies for the 
treatment of diabetes is maintaining postprandial glucose level through inhibition of dipeptidyl peptidase IV (DPP-IV) and α-glucosidase enzymes. 
The aim of this study was to determine in vitro antidiabetic potential of Ferula assa-foetida via DPP-IV and α-glucosidase inhibitory activities.
Methods: F. assa-foetida seeds were extracted in methanol, ethanol, ethanol-methanol, and water. Inhibitory activity on DPP-IV and α-glucosidase was 
performed in vitro and measured spectrophotometrically at λ=405 nm.
Results: The result showed that the F. assa-foetida seed extract is effective against both enzymes. All fractions had DPP-IV inhibitory activity, but 
the ethanolic fraction had the highest inhibitory activity on DPP-IV enzyme and significantly decreased DPP-IV activity (24.5%). With respect to 
α-glucosidase inhibitory activity, the aqueous extract has the highest inhibitory activity (28%).
Conclusion: According to the results of this study, F. assa-foetida contains DPP-IV and α-glucosidase inhibitors and could be a potential source for the 
discovery of active constituents as α-glucosidase and DPP-IV inhibitors to treat Type 2 DM.
Keywords: Diabetes mellitus, Herbal medicine, Dipeptidyl peptidase IV, α-glucosidase.
INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic disorders in which the 
body cannot effectively use the insulin, has defects in insulin secretion 
or both, that lead to high blood glucose. Type 2 DM (T2DM) is the most 
common type of this disease and accounts for at least 90% of all cases 
of diabetes [1]. Although in most patients with T2DM, there may be no 
obvious symptoms for a long period, it still threatens human health. 
Blurred vision, drowsiness, weight gain, numbness in hands and feet, 
and gum disease are some symptoms of T2DM in patient [2].
The incidence of T2DM is rising dramatically worldwide. According to 
the International Diabetes Federation, 425 million people are affected 
by diabetes worldwide, every 6 seconds one person dies from diabetes 
with 5 million deaths reported in 2015 and diabetes expenditure 
reached USD 1.197 billion [3].
At first, T2DM can be managed by lifestyle changes that include diet and 
exercise, but due to the progressive nature of this disease, exercise and 
proper diet may not completely solve the problem so oral hypoglycemic 
drugs are necessary to treat T2DM. Insulin therapy is the most effective 
treatment, generally used in advanced stages of T2DM when other 
therapeutic strategies are no longer effective [4-6].
Based on the pathogenic mechanisms of T2DM, various medications 
have been produced and are prescribed for patients according to 
symptoms of disease. α-glucosidase inhibition is one of the mechanisms 
of action of these medications. α-glucosidase plays a role in the 
conversion of carbohydrates into glucose. By inhibiting α-glucosidase, 
glucose levels in the blood can be returned to normal limits. Hence, use 
of pharmaceuticals that inhibit activity of this digestive enzyme could be 
a good treatment for T2DM. The most recent medications used to treat 
T2DM are inhibitors of dipeptidyl peptidase IV (DPP-IV). DPP-IV rapidly 
destroys the incretin hormones, glucagon-like peptide-1 (GLP-1) and 
gastric inhibitory polypeptide (GIP). These peptides are members of 
the glucagon peptide superfamily that helps the body produce more 
insulin when it is needed [1,7-11].
Nowadays, several DPP-IV inhibitors are available that can be taken 
orally in tablet form. Synthetic oral hypoglycemic drugs are the most 
common form of treatment for T2DM, but they have undesirable side 
effects in patients with T2DM [4]. Moreover, these drugs impose a high 
cost to patients and sometimes, especially in developing countries, the 
majority of patients cannot afford the high cost of the drugs. Therefore, 
research on medicinal plants as inexpensive resources containing 
valuable pharmaceutical metabolites and identification of drugs with 
high efficiency and lower side effects is essential.
Ferula assa-foetida L. is an important medicinal plant belonging to the 
Apiaceae family with many medicinal benefits. “Asafoetida” derived 
from the Persian word “asa” (resin) and Latin foetida that means 
“odorous,” refers to its strong sulfurous odor.
According to the literatures, this herbaceous perennial plant is found in 
central Asia, Iran to Afghanistan, from which it is exported to the entire 
world. Traditionally, it is used for the treatment of different diseases, 
such as stomach ache, asthma, epilepsy, flatulence, weak digestion, 
intestinal parasites and influenza [12]. Recent pharmacological 
and biological studies have also shown several activities, such as 
antioxidant [13], antiviral [14], antimicrobial [15], antispasmodic and 
hypotensive [16], and antidiabetic [5,17].
Nowadays identification of more efficient pharmaceuticals with 
less side effects and understanding the mechanism of action of 
hypoglycemic activity of medicinal plants is an important matter. Since 
the antidiabetic effects of F. assa-foetida L. have been proven in in vivo 
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studies, but the exact mechanism(s) of blood glucose-lowering effect of 
this herb is not well-known, so this study was carried out to investigate 
the α-glucosidase and DPP-IV inhibitory activities of Ferula asafetida L. 
as two of the most important hypoglycemic mechanisms.
MATERIAL AND METHODS
Chemicals
DPP-IV from porcine kidney, Gly-Pro p-nitroanilide p-toluenesulfonate, 
α-glucosidase from Saccharomyces cerevisiae, 4-nitrophenyl α-D-
glucopyranoside, and Acarbose purchased from Sigma. All other 
chemicals used for the experiment were of analytical grade.
Sample preparation
The F. assa-foetida seeds were collected and then powdered using 
grinder. 25 g of powdered plant seed were extracted with 50 ml 
methanol, ethanol, methanol-ethanol and water on an orbital shaker for 
24 hrs. The resulting extracts were filtered using Whatman No. 1 filter 
paper to remove plant debris, and the filtrate was allowed to dry under 
a stream of air at room temperature. Dried extracts were weighed and 
dissolved in dimethylsulphoxide to yield a stock solution. The solution 
was stored at 4°C for subsequent use.
α-glucosidase inhibitory activity assay
The α-glucosidase inhibition was determined using the modified method 
according to Ooi et al. [18]. In brief, the reaction mixture contained 50 
mM 4-nitrophenyl α-D-glucopyranoside as substrate, 50 µL of the extract 
(0.5 mg/ml) or Acarbose (positive control) and 50 µl of α-glucosidase 
(0.05 U/ml) and 50 µl sodium phosphate buffer (0.1 mM, pH 6.9) were 
incubated at 30°C for 40 minutes. Then, the reaction was terminated 
by the addition of 100 µl of 0.2 M sodium carbonate solution and 
absorbance was determined at 405 nm using plate reader.




-glucosidase activity with extract% Inhibition = 
-glucosidase activity without extract
DPP-IV inhibitory activity assay
DPP-IV inhibitory activity assay was performed colorimetrically using 
Gly-Pro p-nitroanilide p-toluenesulfonate as chromogenic substratein 
triplicate following the modified method of Matheeussen et al. [19]. 
DPP-IV cleaves the chromogenic substratetorelease the yellow colored 
product measured at 405 nm. Briefly, in a 96-well plate, DPP-IV 
inhibition test was conducted with the following conditions: 50 µL of 
various extract (0.5 mg/ml) and 50 µL of DPP-IV enzyme (0.01 u/ml) 
were added to each well, pre-incubated at 37°C for 10 minutes, then 
25 µL of the substrate (1.5 mM) was added to the mixture bringing the 
final volume to 200 µL with Tris buffer pH=8, incubated at 37°C and 
the reaction was stopped after 1 hr by adding 100 ml of sodium acetate 
pH=4. Absorbance was taken at 405 nm by ELx808LBS Absorbance 
Plate Reader (Bio-TEK, USA).
The results obtained were compared with the negative control 
(no inhibitor).
Percentage of inhibition was calculated by the following formula:
DPP - IV activity with extract% Inhibition = 
DPP - IV activity without extract
× 100
RESULTS AND DISCUSSION
α-glucosidase inhibitory activity assay
Inhibition of the α-glucosidase that retards the liberation of glucose 
from dietary complex carbohydrates is one of the important methods to 
delay the absorption of glucose from the digestive system. Nowadays, 
one group of drugs that is used to treat T2DM are this kind of inhibitors, 
but due to the cost of synthetic drugs and their side effects, finding 
more efficient and safer drugs is crucial. Therefore, the use of herbs 
as alternative medicine as well as to find valuable pharmaceutical 
metabolites has significant value, especially for the treatment of 
diabetes. In this study, the results of the α-glucosidase inhibitory 
activity assay showed that aqueous extract of Asafoetida seed had 
strong inhibitory activity (Table 1), and this inhibitory activity was 
concentration-dependent. So that by increasing the concentration of 
extract from 0.1 to 1 mg/L, the inhibitory activity increased dramatically 
from 10% to 40% (Fig. 1).
Although it has long been proven that assa-foetida has anti-diabetic 
activity, the glucose-lowering mechanisms of this plant are not clearly 
known. When streptozotocin-induced diabetic rats were treated 
with the Asafoetida extract at a dose of 50 mg/kg, the serum glucose 
concentration decreased significantly in comparison with untreated 
diabetic rats [20]. Hence, one possible reason for the decreased blood 
glucose level caused by Asafoetida extract in streptozotocin-induced 
diabetic rats could be due to having inhibitory effect on glucosidase 
enzyme activity. Because our result showed that Asafoetida has 
inhibitory effect on this enzyme.
In another study to find out the mechanisms of the blood glucose 
lowering action of assa-foetida, the glucose transporter type 4 (GLUT4) 
was studied in C2C12 cell. Data indicated that assa-foetida treatment 
increases translocation of the GLUT4 to the cell membrane which may 
be one of the possible mechanisms of antihyperglycemic effect of assa-
foetida [21].
According to our results, α-glucosidase inhibition is one of the main 
mechanisms of antihyperglycemic activity of Asafoetida and thereby 
reduces blood glucose.
Several studies have been conducted to evaluate α-glucosidase 
inhibitory activity of medicinal plants as an important antidiabetic 
factor. For instance, Hasimun et al. evaluated α-glucosidase inhibitory 
activity of Zingiberaceae family and found that selected members of 
this family Hada varied range of IC50 from 28.4 μg/ml to 269.2 μg/ml 
against α-glucosidase. So concluded that the Zingiberaceae family has 
good potential for use as an alternative medicine to treat DM [22].
Table 1: Percent reduction in α-glucosidase enzyme activity by 
different extracts of F. assa-foetida seed






F. assa-foetida: Ferula assa-foetida
Fig. 1: α-glucosidase inhibitory activity of different 
concentrations of aqueous extract of Ferula assa-foetida seed
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Furthermore, α-glucosidase inhibitory activity of Abutilon indicum 
was investigated and IC50 of the A. indicum methanolic leaf extract 
on α-glucosidase was 137.61 μg/ml indicates that this plant has good 
potential antidiabetic activity [23].
DPP-IV inhibitory activity
This approach is the latest treatment method to deal with T2DM, 
including inhibition of DPP-IV enzyme that breaks down GLP-1, the 
insulin secretion stimulating peptides, and reduces its half-life to just 
under 2 minutes. Due to the disadvantages mentioned on chemical 
medicines and the benefits of herbs and natural metabolites, assa-
foetida was studied to identify the possible mechanisms of antidiabetic 
activity. Results showed that all four fractions of methanolic, ethanolic, 
methanol-ethanolic and water extract had DPP-IV inhibitory properties, 
but it is noteworthy that ethanolic and ethanol-methanolic fractions 
had the highest inhibitory activity and aqueous fraction showed the 
lowest inhibition activity (Table 2).
According to the results of this study, assa-foetida probably reduces 
blood glucose by inhibiting α-glucosidase and DPP-IV activity, leading 
to reduce glucose absorption from the digestive system and stimulating 
the production of insulin by increasing the half-life of GLP-1, 
respectively. The results of some in vivo studies showed that the use of 
Asafoetida increases the amount of insulin in diabetic mice.
Yusufoglu suggested that the antihyperglycemic effects of assa-foetida 
could be due to its insulin-secreting activity. Administration of F. assa-
foetida (200 and 400 mg/kg) extract to diabetic rats increased the 
levels of insulin compared to the diabetic control rats [17]. Forasmuch 
as GLP-1 has a potent effect on insulin secretion so when the GLP-1-
degrading enzyme is inhibited (DPP-IV) by an inhibitor, the level of 
GLP-1 will increase and induces insulin secretion and finally the blood 
glucose decreases.
The effectiveness of medicinal plants in reducing blood glucose and 
increasing plasma insulin levels has been proven in many studies.
Feeding the streptozotocin-induced diabetic rats with the powdered 
Du-zhong (Eucommia ulmoides Oliv.) leaves and its aqueous extract for 
3 weeks based on 1% dried Du-zhong leaves, reduced plasma glucose 
occurred simultaneously with the increase in plasma insulin [24].
To evaluate antidiabetic effect of Caulerpa lentillifera, the inhibitory 
effect of C. lentillifera extract on DPP-IV and α-glucosidase activity was 
measured in a cell-free system. Results showed that C. lentillifera extract 
significantly decreased DPP-IV and α-glucosidase activities and, therefore, 
C. lentillifera could be used as a potential anti-diabetic agent [25].
Methanolic leaf extract of Mangifera indica [26], hexane extract of 
Annona squamosal [27], the ethanolic extract of Urena lobate [28], and 
the aqueous leaves extract of Cistus incanus L. [29] is some studies that 
have inhibited DPP-IV enzymatic activity. The level of plasma GLP-1 in 
rats treated with the polar fraction of Pueraria tuberosa was increased 
that it was due to the inhibitory effects on DPP-IV enzyme [30].
CONCLUSION
T2DM is the most common type of diabetes. Symptoms such as blurred 
vision, drowsiness, weight gain, numbness in hands and feet, and gum 
disease are some symptoms of T2DM in patients [31]. According to 
the International Diabetes Federation report, 425 million people are 
affected by diabetes worldwide; every 6 seconds one person dies from 
diabetes [3].
Up to now various medications have been produced and α-glucosidase 
inhibition is one of these medications. By inhibiting α-glucosidase, 
glucose levels in the blood can be returned to normal limits. Hence, the 
inhibitory activity of this digestive enzyme can be a good treatment for 
T2DM.
The most recent medications used to treat T2DM are inhibitors of the 
DPP-IV enzyme. DPP-IV rapidly destroys the incretin hormones, GLP-1 
and GIP. These peptides help the body produce more insulin when it is 
needed.
Synthetic oral hypoglycemic drugs are the most common form of 
treatment for T2DM, but they have undesirable side effects in patients 
with T2DM and also these drugs impose a high cost to patients. 
Therefore, research on medicinal plants as inexpensive resources 
containing valuable pharmaceutical metabolites is essential. F. assa-
foetida L. is an important medicinal plant belonging to the Apiaceae, 
traditionally used for the treatment of different diseases and recent 
pharmacological and biological studies have shown its anti-diabetic 
activities.
Considering the importance of identification of more efficient drugs 
with less side effects and also understanding the mechanism of action of 
hypoglycemic plants and since the antidiabetic activity of F. assa-foetida 
has not previously been investigated mechanistically, this study was 
done to investigate the α-glucosidase and DPP-IV inhibitory activities 
of F. assa-fetida. In conclusion, the results of this study suggest that 
F. assafoetida through DPP-IV and α-glucosidase inhibitory activities 
can be involved in the blood glucose control and could be recommended 
for the treatment of T2DM.
ACKNOWLEDGMENT
The authors would like to thank Farzaneh Aram and Mehdi 
Farahmandzadeh, staff at the Biotechnology Institute of the Shiraz 
University for their helps and support. This work was supported by 
grants from the University of Guilan.
REFERENCES
1. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 
2007;21(4):517-33.
2. Rosenthal MS. The Canadian Type 2 Diabetes Sourcebook. Canada: 
John Wiley & Sons Canada, Ltd.; 2009. p. 34.
3. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, 
Belgium: International Diabetes Federation; 2015. Available from: 
http://www.diabetesatlas.org.
4. Brunetti L, Kalabalik J. Management of Type-2 diabetes mellitus 
in adults: Focus on individualizing non-insulin therapies. P T 
2012;37(12):687-96.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, 
Nauck M, et al. Management of hyperglycemia in Type 2 diabetes: 
A patient-centered approach position statement of the American 
Diabetes Association (ADA) and the European Association for the 
Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
6. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, 
et al. Weight management through lifestyle modification for the 
prevention and management of Type 2 diabetes: Rationale and strategies 
a statement of the American Diabetes Association, the North American 
Association for the Study of Obesity, and the American Society for 
Clinical Nutrition. Diabetes Care 2004;27:2067-73.
7. Barnett A. DPP-4 inhibitors and their potential role in the management 
of Type 2 diabetes. Int J Clin Pract 2006;60(11):1454-70.
8. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl 
peptidase-4 (DPP-4) inhibitors for Type 2 diabetes mellitus. Cochrane 
Database Syst Rev 2008;CD006739.
9. Tiwari P. Recent trends in therapeutic approaches for diabetes management: 
A comprehensive update. J Diabetes Res 2015;2015:340838.
Table 2: DPP-IV inhibitory activity of different extractions of 
F. assa-foetida seed





DPP-IV: Dipeptidyl peptidase IV, F. assafoetida: Ferula assafoetida
360
Asian J Pharm Clin Res, Vol 10, Issue 5, 2017, 357-360
 Yarizade et al. 
10. van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of 
Type 2 diabetes. Vasc Health Risk Manag 2008;4(6):1189-95.
11. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, 
Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with 
Type 2 diabetes: Results from a Cochrane systematic review and meta-
analysis. Diabetes Care 2005;28(1):154-63.
12. Iranshahy M, Iranshahi M. Traditional uses, phytochemistry and 
pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin): 
A review. J Ethnopharmacol 2011;134(1):1-10.
13. Dehpour AA, Ebrahimzadeh MA, Fazel NS, Mohammad NS. 
Antioxidant activity of the methanol extract of Ferula assa-foetida and 
its essential oil composition. Grasas Aceites 2009;60:405-12.
14. Lee CL, Chiang LC, Cheng LH, Liaw CC, Abd El-Razek MH, 
Chang FR, et al. Influenza A (H1N1) antiviral and cytotoxic agents 
from Ferula assa-foetida. J Nat Prod 2009;72:1568-72.
15. Patil SD, Shinde S, Kandpile P, Jain AS. Evaluation of antimicrobial 
activity of asafoetida. Int J Pharm Sci Res 2015;6:722-7.
16. Fatehi M, Farifteh F, Fatehi-Hassanabad Z. Antispasmodic 
and hypotensive effects of Ferula assa-foetida gum extract. J 
Ethnopharmacol 2004;91(2-3):321-4.
17. Yusufoglu HS, Soliman GA, Abdel-Rahman RF, Abdel-Kader MS, 
Ganaie MA, Bedir E, et al. Antihyperglycemic and antihyperlipidemic 
effects of Ferula assa-foetida and Ferula tenuissima extracts in diabetic 
rats. Pak J Biol Sci 2015;18:314-23.
18. Ooi KL, Muhammad TS, Tan ML, Sulaiman SF. Cytotoxic, apoptotic 
and anti-α-glucosidase activities of 3, 4-di-O-caffeoyl quinic acid, an 
antioxidant isolated from the polyphenolic-rich extract of Elephantopus 
mollis Kunth. J Ethnopharmacol 2011;135(3):685-95.
19. Matheeussen V, Lambeir AM, Jungraithmayr W, Gomez N, Mc Entee K, 
van der Veken P, et al. Method comparison of dipeptidyl peptidase IV 
activity assays and their application in biological samples containing 
reversible inhibitors. Clin Chim Acta 2012;413(3-4):456-62.
20. Iranshahi M, Alizadeh M. Antihyperglycemic effect of asafoetida 
(Ferula assa-foetida Oleo-Gum-Resin) in streptozotocin-induced 
diabetic rats. World Appl Sci J 2012;17:157-62.
21. Azari M, Mohiti-ardekani J, Abedini S, Mozayan MR. Effect of Ferula 
assa-foetida on cytoplasmic membrane glucose transporter isotype-4 of 
C2C12 cell line. Int J Med Lab 2014;1:46-53.
22. Hasimun P, Adnyana IK, Valentina R, Lisnasari E. Potential alpha-
glucosidase inhibitor from selected Zingiberaceae family. Asian J 
Pharm Clin Res 2016;9:164-7.
23. Pant G, Sai K, Babasaheb S, Reddy R, Sibi G. In vitro α-amylase and 
α-glucosidase inhibitor activities of Abutilon indicum leaves. Asian J 
Pharm Clin Res 2013;6:22-4.
24. Lee MK, Kim MJ, Cho SY, Park SA, Park KK, Jung UJ, et al. 
Hypoglycemic effect of Du-zhong (Eucommia ulmoides Oliv.) leaves 
in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 
2005;67:22-8.
25. Sharma BR, Rhyu DY. Anti-diabetic effects of Caulerpa lentillifera: 
Stimulation of insulin secretion in pancreatic β-cells and enhancement of 
glucose uptake in adipocytes. Asian Pac J Trop Biomed 2014;4:575-80.
26. Yogisha S, Raveesha KA. Dipeptidyl peptidase IV inhibitory activity of 
Mangifera indica. J Nat Prod 2010;3:76-9.
27. Davis JA, Sharma S, Mittra S, Sujatha S, Kanaujia A, Shukla G, 
et al. Antihyperglycemic effect of Annona squamosa hexane extract in 
Type 2 diabetes animal model: PTP1B inhibition, a possible mechanism 
of action. Indian J Pharmacol 2012;44:326-32.
28. Purnomo Y, Soeatmadji DW, Sumitro SB, Widodo MA. Anti-diabetic 
potential of Urena lobata leaf extract through inhibition of dipeptidyl 
peptidase IV activity. Asian Pac J Trop Biomed 2015;5:645-9.
29. Lendeckel U, Arndt M, Wolke C, Reinhold D, Kähne T, Ansorge S. 
Inhibition of human leukocyte function, alanyl aminopeptidase (APN, 
CD13) and dipeptidylpeptidase IV (DP IV, CD26) enzymatic activities 
by aqueous extracts of Cistus incanus L. ssp. incanus. J Ethnopharmacol 
2002;79:221-7.
30. Srivastava S, Koley TK, Singh SK, Tripathi YB. The tuber extract of 
Pueraria tuberosa Linn. Competitively inhibits DPP-IV activity in 
normoglycemic rats. Int J Pharm Pharm Sci 2015;15:227-31.
31. American Diabetes Association. 2. Classification and diagnosis of 
diabetes. Diabetes Care 2015;38 Suppl 1:8-16.
